The American Journal of Managed Care

Exploring CAR T-Cell Therapy Efficacy in Earlier Vs Later Lines of Therapy

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...
Healio

First-line immunotherapy underutilized in kidney cancer; ‘different mechanisms’ needed

Please provide your email address to receive an email when new articles are posted on . Immune checkpoint inhibitor-based combinations are the preferred first-line therapy for metastatic clear cell ...
The American Journal of Managed Care

Navigating First-Line Therapy Guidelines and Treatment Considerations in High-Risk Cytogenetics

Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for ...
Medscape

First-Line Urate-Lowering Therapy for Gout: Xanthine Oxidase Inhibitor or Mechanism-Based Approach?

For gout, xanthine oxidase (XO) inhibitors are the choice for first-line urate-lowering therapy (ULT) according to the 2020 American College of Rheumatology Guideline for the Management of Gout, which ...
FiercePharma

Pfizer's Tukysa delays HER2 breast cancer progression as 1st-line maintenance therapy

Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. The current standard of care for the ...
Business Wire

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA ® (tucatinib) as part of an ...